drugset / Trial / NCT00630409
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the hypothesis that the combination of gemcitabine and doxil will have clinical activity in patients with metastatic renal cell carcinoma.
Timeline
- Start
- 2004-09
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 24 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 800 mg | Intravenous |